Back to News
Oct 10, 2025 12:00 PM

Bristol Myers Expands Cell Therapy Portfolio With Orbital Therapeutics Acquisition

Bristol Myers Squibb & Co. (NYSE:BMY) on Friday agreed to acquire Orbital Therapeutics, a privately held biotechnology company focused on RNA medicines that reprogram the immune system in vivo.

The US drug giant agreed to pay $1.5 billion in cash.

“In vivo CAR T represents a novel treatment approach that could redefine how we treat autoimmune diseases,” said Robert Plenge, executive vice president, Chief Research Officer, BMS. “This acquisition enhances our robust cell therapy research platform and provides an opportunity to advance a potential best-in-class ...